

Errata

Br J Clin Pharmacol 1999; **48**: 402–408.

‘Genetic polymorphism of S-mephenytoin 4′-hydroxylation in populations of African descent.’

H. G. Xie, R. B. Kim, C. M. Stein, G. R. Wilkinson & A. J. J. Wood

- p. 403 The last sentence of paragraph 2 of **Methods** should read ‘these single-point mutations remove respectively, restriction endonucleases *Bam*H1 and *Sma*1 sites [5, 6, 10, 18–21, 27–30].’
- p. 406 In the first line of the left hand column ‘under of the control of’ should read ‘under the control of’.

Br J Clin Pharmacol 2001; **52**: 201–204.

‘Effects of suprathreshold doses of ebastine and terfenadine on the QT interval’.

Michael S. Gillen, Barry Miller, Philip Chaikin & Joel Morganroth

The address for correspondence should be ‘AstraZeneca, 725 Chesterbrook Boulevard, Wayne, PA 19087, USA’.

- p. 202 The last sentence of the *Pharmacodynamic results* section should read ‘Terfenadine caused a 14.1 ms increase in QTcF, which was significantly greater ($P < 0.0001$) than the other three treatments’.
- p. 203 Table 2, column 8. The 95% CI for ebastine *vs.* terfenadine for mean HR (beats min^{-1}) should be [1.44, 5.56] and [3.14, 7.26] instead of [1.5, 44.56] and [3.7, 14.26].